In situ androgen producing enzymes in human prostate cancer

Yasuhiro Nakamura1,2, Takashi Suzuki1, Masao Nakabayashi1, Mareyuki Endoh1, Kazuhiro Sakamoto1, Yoshiki Mikami1, Takuya Moriya1, Akihiro Ito3, Shoki Takahashi2, Shogo Yamada2, Yoichi Arai3 and Hironobu Sasano1

Departments of 1Pathology, 2Radiology, and 3Urology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575 Japan

(Requests for offprints should be addressed to Y Nakamura; Email: nakamura@patholo2.med.tohoku.ac.jp)

Abstract

Androgens have been proposed to be actively produced in situ in human prostate cancer. These locally produced androgens have also been considered to play important roles in the pathogenesis and development of prostate cancer. Therefore, it is important to examine the status of this in situ androgen metabolism and/or synthesis in detail in order to improve the clinical response to hormonal therapy in patients diagnosed with prostate cancer. Several studies have previously demonstrated the expression of androgen-producing enzymes such as 5α-reductase types 1 and 2, and 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5), in human prostate carcinoma cells. However, their biological significance has remained largely unknown. In this study, we evaluated the immunoreactivities of these steroidogenic enzymes in human prostate cancer obtained from surgery (n=70), and correlated the findings with clinicopathological features of the patients. 17β-HSD5 immunoreactivity was detected in 54 cases (77%), 5α-reductase type 1 in 51 cases (73%) and 5α-reductase type 2 in 39 cases (56%). 5α-reductase type 2 immunoreactivity was significantly correlated with that of androgen receptor (AR), and 17β-HSD5 positive cases were significantly associated with clinical stage (TNM stage pT3 vs pT2). These data all suggest that androgen-producing enzymes, such as 5α-reductase type 1 and type 2, and 17β-HSD5 are expressed in a majority of prostate cancers, and are involved in the local production and actions of androgens in prostate cancers.

Endocrine-Related Cancer (2005) 12 101–107

Introduction

Androgens play important roles in the pathogenesis of prostate cancer (Lopez-Otin & Diamandis 1998). In addition, the in situ production of androgens has been proposed to play a critical role in the pathogenesis and/or development of human prostate cancer (Lopez-Otin & Diamandis 1998). Moreover, suppression of androgen secretion and/or a blockade of their actions represent the basis for many forms of effective hormonal treatment of patients diagnosed with prostate cancer (Negri-Cesi et al. 1998). Therefore, it is very important to examine the status of expression of androgen metabolizing and/or producing enzymes in prostate cancer patients in order to obtain a better understanding of the possible roles of in situ androgen production and its action.

Testosterone, the main circulating androgen, is converted in prostate cancer tissues by 5α-reductases into the bioactive and potent androgen, 5α-dihydrotestosterone (DHT) (Russell & Wilson 1994). Therefore, 5α-reductases are considered to play important roles as local regulators of androgen and other sex steroid actions in prostate cancer tissues. The type 1 isozyme of 5α-reductase is located on the distal short arm of chromosome 5, and is mainly expressed in the liver and skin (Thigpen et al. 1993, Russell & Wilson 1994). The type 2 isozyme of 5α-reductase is located in band p23 of chromosome 2, and is, in addition to its strong expression in the liver, also markedly expressed in the prostate, seminal vesicle, and epididymis (Thigpen et al. 1992, Thigpen et al. 1993). In a recent study by Dufort and co-workers, 17β-HSD5, which specifically catalyzes the reduction
of androstenedione to testosterone, was cloned (Dufort et al. 1999). Several studies have previously demonstrated the presence of 5α-reductase isozyme mRNAs and enzyme activities in human prostate carcinoma cells (Delos et al. 1998, Negri-Cesi et al. 1998, Soderstrom et al. 2002, Thomas et al. 2003). The mRNA for 17β-HSD5 was also reported to be expressed in prostate cancer tissues (Koh et al. 2002). These findings indicate that in situ production of 5α-dihydrotestosterone (DHT) from inactive androstenedione by 17β-HSD5 (reduction of androstenedione to testosterone), and via 5α-reductase (metabolism of testosterone to DHT) in human prostate tissue may be occurring. However, the status of expression for these enzymes and their relation to clinicopathological findings has not been examined in human prostate cancer. Therefore, in this study, we first examined the immunolocalization of 5α-reductase isoforms, and 17β-HSD5 in human prostate carcinoma tissue specimens obtained from surgery. We then correlated these findings with various clinicopathological parameters of patients including the status of the androgen receptor (AR) in 70 cases of human prostate carcinoma in order to evaluate the possible roles of these androgen metabolizing/synthesizing enzymes in human prostate cancer.

Materials and methods
Patients and tissues
Seventy surgical pathology specimens of prostate carcinoma were obtained from patients who underwent prostatectomy from 1998–2003 at the Department of Urology, Tohoku University Hospital (Sendai, Japan). The mean age of the patients was 65.7 years (range: 48–77). All patients examined in this study did not receive radiation, chemotherapy, or hormone therapy before surgery. Clinical data, including patient age, serum prostate specific antigen (PSA) concentration, clinical stage according to the International Union Against Cancer TNM classification (1987), lymph node status, and Gleason’s score (Veltri et al. 1996) were retrieved from detailed patient charts describing individual patient histories. The histological grade of each tumor was evaluated by three of the authors (Y N, T S and H S). All specimens were fixed with 10% formalin and embedded in paraffin wax at the Department of Pathology, Tohoku University Hospital. The Ethic’s Committee at Tohoku University School of Medicine approved the research protocol for this study.

Antibodies
5α-reductase type 1 and type 2 antibodies used in this study were rabbit polyclonal antibodies against synthesized peptides corresponding to amino acids 232–256 for 5α-reductase type 1, and amino acids 227–251 for 5α-reductase type 2, respectively (Thigpen et al. 1993). These antibodies were kindly provided by Dr D W Russell (University of Texas Southwestern Medical Center, Dallas, TX). The polyclonal antibody for 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) was raised in a rabbit against a synthetic peptide corresponding to amino acids 297–320 for 17β-HSD5 and was kindly provided by Dr V Luu (Laval University Hospital Center, Quebec, Canada) (Pelletier et al. 1999). Characterization of these three antibodies was confirmed by immunoblotting, and the use of antibodies for 5α-reductase type 2 and 17β-HSD5 on immunohistochemistry has been previously reported (Thigpen et al. 1993, Silver et al. 1994, Pelletier et al. 1999). mAb against AR was purchased from DAKO Corporation (Carpinteria, CA).

Immunohistochemistry
Immunohistochemical analysis was performed employing the streptavidin-biotin amplification method using a Histofine Kit (Nichirei, Tokyo, Japan) and has been previously described in detail (Suzuki et al. 1994). For immunostaining of AR, the slides were heated in an autoclave at 120°C for 5 min in citric acid buffer (2 mmol/l citric acid and 9 mmol/l trisodium citrate dehydrate, pH 6.0) after deparaffinization for antigen retrieval. The dilutions of primary antibodies used in our study were as follows: 5α-reductase type 1, 1:1000; 5α-reductase type 2, 1:1000; AR, 1:100; and 17β-HSD5, 1:1000. The antigen–antibody complex was visualized with 3,3’-diaminobenzidine (DAB) solution [1 mmol/l 3,3’-DAB, 50 mmol/l Tris–HCl buffer (pH 7.6), and 0.006% H2O2] and counterstained with hematoxylin. Tissue sections of liver and prostate were used as positive controls for 5α-reductase types 1 and 2, respectively, and non-neoplastic breast tissue was used as a positive control for 17β-HSD5 (Thigpen et al. 1993, Pelletier et al. 1999). As a negative control, normal rabbit or mouse IgG was used instead of the primary antibodies, and no specific immunoreactivity was detected in these reported tissue sections.

Scoring of immunoreactivity
Scoring of immunoreactivity was performed based on previous reports with some modifications (Soslow et al.
2000, Suzuki et al. 2001). For statistical analyses of 5α-reductase type 1 and type 2, and 17β-HSD5 immunoreactivity, the carcinoma cases were classified into the following two groups: +, positive, more than 10% positive cells; and −, no immunoreactivity, less than 10% positive cells according to Soslow and colleagues (Soslow et al. 2000). The evaluation (+, positive carcinoma cells; and −, no immunoreactivity) was performed by three of the authors (Y N, T S and H S), independently. Cases with discordant results among these investigators above were re-evaluated. Scoring of AR in carcinoma cells was performed on high power fields (× 400) using standard light microscopy. In each case, more than 500 carcinoma cells were counted independently by the three authors above, and the percentage of immunoreactivity, i.e. labeling index (LI), was determined (Suzuki et al. 2001). In the present study, interobserver differences were less than 5%, and the mean of these three values was obtained. In addition, as a control, immunoreactivity for 5α-reductase type 1 and 2, 17β-HSD5, and AR was examined in the peripheral zone of non-neoplastic glands in each case.

**Statistical analysis**

Values for patient age, serum PSA levels, and LI for AR were presented as the mean ± 95% confidence interval (95% CI), and associations between 5α-reductase immunoreactivity and the parameters described above were evaluated using the Bonferroni test. Statistical differences between immunoreactivity for 5α-reductases and stage, lymph node status, histological grade, and immunoreactivity for 17β-HSD5, were evaluated in a cross-table using the χ²-test. P < 0.05 was considered significant.

**Results**

**Immunohistochemistry**

Immunoreactivity for 5α-reductase type 1 and type 2, and 17β-HSD5 was detected in the cytoplasm of carcinoma cells, whereas AR immunoreactivity was detected in the nuclei of carcinoma cells (Fig. 1A–D). In the non-neoplastic peripheral zone, immunoreactivity for 5α-reductase type 2, 17β-HSD5, and AR was detected in the glandular epithelium, but

![Figure 1](image-url)
5α-reductase type 1 immunoreactivity was negative in this study (Fig. 1E–H). The number of positive cases and their corresponding percentages were as follows: 51/70 (73%) for 5α-reductase type 1, 39/70 cases (56%) for 5α-reductase type 2, and 54/70 cases (77%) for 17β-HSD5.

**Correlation among 5α-reductases and 17β-HSD5 immunoreactivity**

A statistically significant positive correlation was detected between 5α-reductase type 1 and type 2 immunoreactivity ($P=0.0004$), and between 5α-reductase type 2 and 17β-HSD5 immunoreactivity ($P=0.0049$) (Table 1) A similar trend was also detected between 5α-reductase type 1 and 17β-HSD5 immunoreactivity, but the correlation did not reach statistical significance ($P=0.0993$) (Table 1).

**Correlation between immunoreactivities and clinicopathological parameters**

Immunoreactivity for 5α-reductase type 1 was not significantly correlated with clinicopathological parameters including patient age, concentration of serum PSA levels, Gleason’s score, pT stage, lymph node status, and AR LI (Table 2) There was a statistically positive correlation between 5α-reductase type 2 immunoreactivity and AR LI ($P=0.0281$) (Table 3), however, it was not significantly correlated with other clinicopathological parameters (Table 3).

17β-HSD5 immunoreactivity was significantly associated with clinical stage in this study (TNM stage pT3 vs pT2) ($P=0.0115$) (Table 4).

**Discussion**

It is well known that androgens play important roles in the pathogenesis of prostate cancer (Lopez-Otin &

---

**Table 1** Correlation among 5α-reductases immunoreactivity and 17β-HSD type 5 immunoreactivity in human prostate cancer

<table>
<thead>
<tr>
<th></th>
<th>5α-reductase type 1 and 5α-reductase type 2</th>
<th>5α-reductase type 1 and 17β-HSD type 5</th>
<th>5α-reductase type 2 and 17β-HSD type 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>$P$ value</td>
<td>0.0004*</td>
<td>0.0993</td>
<td>0.0049*</td>
</tr>
</tbody>
</table>

* $P < 0.05$.

---

**Table 2** Correlation between 5α-reductase type 1 immunoreactivity and clinicopathological parameters in human prostate cancer

<table>
<thead>
<tr>
<th></th>
<th>+ (n=51)</th>
<th>- (n=19)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65.2 ± 0.9</td>
<td>66.6 ± 1.3</td>
<td>0.3851</td>
</tr>
<tr>
<td>PSA (ng/ml)</td>
<td>14.0 ± 1.8</td>
<td>17.2 ± 4.0</td>
<td>0.6540</td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2–6</td>
<td>8 (11.4%)</td>
<td>5 (7.1%)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>22 (31.4%)</td>
<td>10 (14.3%)</td>
<td>0.2612</td>
</tr>
<tr>
<td>8–10</td>
<td>21 (30.0%)</td>
<td>4 (5.7%)</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>20 (28.6%)</td>
<td>9 (12.9%)</td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td>31 (44.3%)</td>
<td>10 (14.3%)</td>
<td>0.5380</td>
</tr>
<tr>
<td>Lymph node status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>6 (8.6%)</td>
<td>2 (2.9%)</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>45 (64.3%)</td>
<td>17 (24.3%)</td>
<td>0.0849</td>
</tr>
<tr>
<td>AR LI (%)</td>
<td>68.1 ± 3.2</td>
<td>69.1 ± 4.0</td>
<td>0.8703</td>
</tr>
</tbody>
</table>

---

**Table 3** Correlation between 5α-reductase type 2 immunoreactivity and clinicopathological parameters in human prostate cancer

<table>
<thead>
<tr>
<th></th>
<th>+ (n=39)</th>
<th>- (n=31)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65.3 ± 1.1</td>
<td>66.0 ± 0.9</td>
<td>0.6203</td>
</tr>
<tr>
<td>PSA (ng/ml)</td>
<td>13.5 ± 1.9</td>
<td>17.0 ± 3.3</td>
<td>0.4390</td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2–6</td>
<td>6 (8.6%)</td>
<td>7 (10.0%)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>19 (27.1%)</td>
<td>13 (18.6%)</td>
<td>0.7203</td>
</tr>
<tr>
<td>8–10</td>
<td>14 (20.0%)</td>
<td>11 (15.7%)</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>14 (20.0%)</td>
<td>15 (21.4%)</td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td>25 (35.7%)</td>
<td>16 (22.9%)</td>
<td>0.2920</td>
</tr>
<tr>
<td>Lymph node status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>3 (4.3%)</td>
<td>5 (7.1%)</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>36 (51.4%)</td>
<td>26 (37.1%)</td>
<td>0.2704</td>
</tr>
<tr>
<td>AR LI (%)</td>
<td>73.4 ± 3.1</td>
<td>62.1 ± 4.0</td>
<td>0.0281*</td>
</tr>
</tbody>
</table>

*Data was considered significant.

---

**Table 4** Correlation between 17β-HSD type 5 immunoreactivity and clinicopathological parameters in human prostate cancer

<table>
<thead>
<tr>
<th></th>
<th>+ (n=54)</th>
<th>- (n=16)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65.5 ± 0.9</td>
<td>65.8 ± 1.1</td>
<td>0.8716</td>
</tr>
<tr>
<td>PSA (ng/ml)</td>
<td>14.7 ± 1.7</td>
<td>13.8 ± 6.2</td>
<td>0.6204</td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2–6</td>
<td>8 (11.4%)</td>
<td>5 (7.1%)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>25 (35.7%)</td>
<td>7 (10.0%)</td>
<td>0.2895</td>
</tr>
<tr>
<td>8–10</td>
<td>21 (30.0%)</td>
<td>4 (5.7%)</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>18 (25.7%)</td>
<td>11 (15.7%)</td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td>36 (51.4%)</td>
<td>5 (7.1%)</td>
<td>0.0115*</td>
</tr>
<tr>
<td>Lymph node status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>7 (10.0%)</td>
<td>1 (1.4%)</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>47 (67.1%)</td>
<td>15 (21.5%)</td>
<td>0.4585</td>
</tr>
<tr>
<td>AR LI(%)</td>
<td>69.4 ± 2.8</td>
<td>64.8 ± 6.1</td>
<td>0.4572</td>
</tr>
</tbody>
</table>

*Data was considered significant.
Diamandis 1998). Although plasma concentrations of testosterone have been shown to decrease more than 90% following castration, androgen levels in prostate cancer tissues decreased only 50–60%, suggesting the importance of in situ androgen production in prostate cancers (Labrie 1991, Mizokami et al. 2004). Results from our present study suggest that androgen-producing enzymes are co-expressed in human prostate cancers, and involved in the local production of DHT, which may play important roles in biological behavior of prostate carcinoma cells.

In the present study, the number of cases positive for steroidogenic enzymes and the corresponding percentages was 39/70 cases (56%) for 5α-reductase type 2. In addition, there was a statistically significant positive correlation between 5α-reductase type 2 immunoreactivity and AR LI. It has been reported that type 2 5α-reductase was expressed in prostate cancer, and was very important in the process of in situ production of DHT (Torres et al. 2003). In addition, type 2 5α-reductase has also been hypothesized to play a role in the pathogenesis and/or development of prostate cancer (Torres et al. 2003). Moreover, it has also been reported that men who have had some polymorphism of the type 2 5α-reductase gene have a significantly increased risk of prostate cancer development and/or progression (Nam et al. 2001). Our data are consistent with these reports, and suggest that 5α-reductase type 2 may play an important role in the in situ production and action of DHT in human prostate cancer tissues.

Results from the present study also demonstrated that 5α-reductase type 1 was frequently expressed in human prostate cancer (73%). In addition, we demonstrated that a significant positive correlation was demonstrated between 5α-reductase type 1 and type 2 immunoreactivity. It has been suggested that individuals with greater 5α-reductase are at an increased risk for developing prostate cancer. Furthermore, previous reports have demonstrated that type 1 5α-reductase mRNA and activity were much greater in prostate cancers than in benign prostate tissues (Steers 2001, Iehle et al. 1999). These data suggest that both type 1 and type 2 5α-reductases are likely to be important in the local production and action of DHT in human prostate cancer. It has also been reported that treatment of finasteride, a 5α-reductase type 2 inhibitor, to patients diagnosed with metastatic prostate cancer resulted in only minor effects in this cancer (Presti et al. 1992), and decreased serum PSA levels by only 7% in men with advanced adenocarcinoma of the prostate (Bruksky et al. 1997). In contrast, however, dutasteride, which inhibits both type 1 and type 2 5α-reductases, treatment has recently been reported to result in almost complete suppression of intraprostatic DHT, and increased regression of prostate cancer (Andriole et al. 2004). Results from these studies suggest that 5α-reductase type 1, as well as the type 2 isozyme, are associated with the growth of prostate cancer. Furthermore, knowing the expression pattern and profile of 5α-reductase isozymes may be important when considering the use of 5α-reductase inhibitors in reducing the progression of prostate carcinoma in patients diagnosed with this aggressive cancer via the inhibition of in situ DHT production. However, further investigations are required to clarify the role of 5α-reductase isozymes and related steroidogenic enzymes in the pathogenesis of prostrate carcinoma.

Iehle and colleagues demonstrated that 5α-reductase type 1 mRNA is abundantly expressed in the epithelial cells of normal prostate, whereas stromal cells of this glandular tissue demonstrated greatly reduced levels (Iehle et al. 1999). In our study, we could not identify significant immunoreactivity of 5α-reductase type 1 in the non-neoplastic peripheral zone of the prostate. A previous study also demonstrated that type 1 5α-reductase mRNA and activity were much lower in benign prostate tissues than in prostate cancers (Steers 2001). Therefore, protein expression levels of 5α-reductase type 1 in non-neoplastic areas of the human prostate were considered below the limits of detection by immunohistochemistry.

In the present study, 17β-HSD5 immunoreactivity was detected in carcinoma cells of 77% of prostate cancer tissues, and was positively associated with clinical stage (P < 0.05; TNM stage III vs TNM stage II). It is well-known that cell proliferation in the normal prostate and in prostate cancer is mainly controlled by testosterone following intracellular conversion to DHT (Ross & Henderson 1994, Imperato-McGinley et al. 1992). However, it has also been demonstrated that the remodeling of prostate stromal tissue via testosterone may play a role in the early stage of prostate carcinogenesis, which is generally considered to be favorable for tumor development (Li et al. 2001). Therefore, 17β-HSD5 may be involved in increasing the local concentration of testosterone in prostate cancer tissues, resulting in the progression, invasion, and further development of prostate cancer.

In summary, we have demonstrated that 5α-reductase types 1 and 2, and 17β-HSD5 were all detected in the great majority of prostate cancer tissues, and significant positive association was detected between 5α-reductase types 2 and AR and/or 17β-HSD5 and clinical stage. These data also indicate the importance of these androgen metabolizing/synthesizing enzymes.
in the local production and action of androgens in human prostate cancer.

References

Andriole GL, Humphrey P, Ray P, Gleave ME,
Trachtenberg J, Thomas LN, Lazier CB & Rittmaster RS
2004 Effect of the dual 5alpha-reductase inhibitor
dutasteride on markers of tumor regression in prostate

Brown CT & Nuttall MC 2003 Dutasteride: a new 5-alpha
reductase inhibitor for men with lower urinary tract
symptoms secondary to benign prostatic hyperplasia.

Bruisky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek
M, Kaplan I, Kaufman D & Kantoff P 1997 Finasteride
and flutamide as potency-sparing androgen-ablative
therapy for advanced adenocarcinoma of the prostate.
Urology 49 913–920.

Salpa-reductase and 17beta-hydroxysteroid dehydrogenase
expression in epithelial cells from hyperplastic and
malignant human prostate. International Journal of
Cancer 75 840–846.

Dufort I, Rheault P, Huang XF, Soucy P & Luu-The V 1999
Characteristics of a highly labile human type 5 17beta-
hydroxysteroid dehydrogenase. Endocrinology 140
568–574.

Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH,
Gerard H, Chopin D, Raynaud JP & Martin PM 1999
Differences in steroid 5alpha-reductase iso-enzymes
expression between normal and pathological human
prostate tissue. Journal of Steroid Biochemistry and
Molecular Biology 68 189–195.

Imperato-McGinley J, Gautier T, Zirinsky K, Hom T,
Palomo O, Stein E, Vaughan ED, Markis JA, Ramirez
de tArellano E & Kazam E 1992 Prostate visualization
studies in males homozygous and heterozygous for 5
alpha-reductase deficiency. Journal of Clinical
Endocrinology and Metabolism 75 1022–1026.

Koh E, Noda T, Kanaya J & Namiki M 2002 Differential
expression of 17beta-hydroxysteroid dehydrogenase isozyme
genes in prostate cancer and noncancer tissues. Prostate
53 153–159.

Labrie F 1991 Endocrine therapy for prostate cancer.
Endocrinology and Metabolism Clinics of North America
20 845–872.

Li SC, Chen GiF, Chan PS, Choi HL, Ho SM & Chan FL
2001 Altered expression of extracellular matrix and
proteinases in Noble rat prostate gland after long-term

Lopez-Otin C & Diamandis EP 1998 Breast and prostate
cancer: an analysis of common epidemiological, genetic,
and biochemical features. Endocrine Reviews 19 365–396.

Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M,
Koshida K, Honma S, Keller ET & Namiki M 2004 The
adrenal androgen androstenediol is present in prostate
cancer tissue after androgen deprivation therapy and
activates mutated androgen receptor. Cancer Research 64
765–771.

Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet
J, Trachtenberg J, Jewett MA & Narod SA 2001 V89L
polymorphism of type-2, 5-alpha reductase enzyme gene
predicts prostate cancer presence and progression.
Urology 57 199–204.

Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P &
Motta M 1998 Presence of 5-alpha-reductase isozymes and
aromatase in human prostate cancer cells and in benign
prostate hyperplastic tissue. Prostate 34 283–291.

O’Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P &
Hofner K 2003 Improvements in benign prostate
hyperplasia-specific quality of life with dutasteride, the
novel dual 5alpha-reductase inhibitor. BJU International
92 262–266.

Pelletier G, Luu-The V, Tetu B & Labrie F 1999
Immunocytochemical localization of type 5 17beta-
hydroxysteroid dehydrogenase in human reproductive
tissues. Journal of Histochemistry and Cytochemistry 47
731–738.

Presti JC Jr, Fair WR, Andriole G, Sogani PC, Seidmon EJ,
Ferguson D, Ng J & Gormley GJ 1992 Multicenter,
randomized, double-blind, placebo controlled study to
investigate the effect of finasteride (MK-906) on stage D

Ross RK & Henderson BE 1994 Do diet and androgens alter
prostate cancer risk via a common etiologic pathway?
Journal of the National Cancer Institute 86 252–254.

Russell DW & Wilson JD 1994 Steroid 5a-reductase: two
genes/two enzymes. Annual Reviews of Biochemistry 63
25–61.

Silver RI, Wiley EL, Thigpen AE, Guileyardo JM,
McConnell JD & Russell DW 1994 Cell type specific
expression of steroid 5a-reductase 2. Journal of Urology
152 438–442.

Soderstrom T, Wadelius M, Andersson SO, Johansson JE,
Johansson S, Granath F & Rane A 2002 Salpa-reductase
2 polymorphisms as risk factors in prostate cancer.
Pharmacogenetics 12 307–312.

Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan
KN, Masferrer J & Koki AT 2000 COX-2 is expressed in
human pulmonary, colonic, and mammary tumors.
Cancer 89 2637–2645.

Steers WD 2001 5alpha-reductase activity in the prostate.
Urology 58 17–24.

Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S,
Kaneko C, Takeyama J, Moriya T & Sasano H 2001
5alpha-reductases in human breast carcinoma: possible
modulator of in situ androgenic actions. Journal of
Clinical Endocrinology and Metabolism 86 2250–2257.

Suzuki T, Sasano H, Kimura N, Tamura M, Fukaya T,
Yajima A & Nagura H 1994 Immunohistochemical
distribution of progesterone, androgen and oestrogen
receptors in the human ovary during the menstrual


Torres JM, Ruiz E & Ortega E 2003 Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status. Prostate 56 74–79.
